Literature DB >> 7602126

The IL-2 receptor gamma c chain does not function as a subunit shared by the IL-4 and IL-13 receptors. Implication for the structure of the IL-4 receptor.

Y W He1, T R Malek.   

Abstract

The IL-2 receptor (IL-2R) gamma c subunit is also a component of the receptors for IL-4, IL-7, IL-9, and IL-15. The IL-4R and IL-13R appear to share a common subunit, and gamma c was proposed to be this shared subunit. In this study, we have assessed the relative contribution of gamma c to the mouse IL-4R and IL-13R. The MC/9 mast cell line constitutively expresses gamma c and proliferates to IL-4 and IL-13, but only the response to IL-4 was blocked by anti-gamma c mAbs. After transfection of the IL-4- and IL-13-responsive gamma c-negative B9 plasmacytoma with full length (m gamma) or cytoplasmic-tailless gamma c cDNA (m gamma t), only the proliferative response to IL-4 was affected by the surface expression of these gamma c molecules. The inability of m gamma or m gamma t expression to affect IL-13-induced proliferation by B9 indicates that gamma c does not obviously contribute to the IL-13R and does not function as the shared subunit of the IL-4R and IL-13R. This study suggests that there are two distinct IL-4R, one of which is independent of gamma c.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7602126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation.

Authors:  M Goebeler; B Schnarr; A Toksoy; M Kunz; E B Bröcker; A Duschl; R Gillitzer
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

2.  Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha.

Authors:  M G Malabarba; H Rui; H H Deutsch; J Chung; F S Kalthoff; W L Farrar; R A Kirken
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

3.  Interleukin-4-specific signal transduction events are driven by homotypic interactions of the interleukin-4 receptor alpha subunit.

Authors:  S Y Lai; J Molden; K D Liu; J M Puck; M D White; M A Goldsmith
Journal:  EMBO J       Date:  1996-09-02       Impact factor: 11.598

4.  Expression of common gamma chain on peripheral blood mononuclear cells in Crohn's disease.

Authors:  I Kirman; O H Nielsen
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

5.  Homodimerization of the human interleukin 4 receptor alpha chain induces Cepsilon germline transcripts in B cells in the absence of the interleukin 2 receptor gamma chain.

Authors:  H Fujiwara; S H Hanissian; A Tsytsykova; R S Geha
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Biochemical and morphological characterization of vascular and lymphocytic interleukin-4 receptors.

Authors:  B Schnyder; S M Lugli; S Schnyder-Candrian; V M Eng; R Moser; J Banchereau; B Ryffel; B D Car
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

7.  Shared gamma(c) subunit within the human interleukin-7 receptor complex. A molecular basis for the pathogenesis of X-linked severe combined immunodeficiency.

Authors:  S Y Lai; J Molden; M A Goldsmith
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

8.  Overexpression of interleukin-4 in lungs of mice impairs elimination of Histoplasma capsulatum.

Authors:  Lucy A Gildea; Reta Gibbons; Fred D Finkelman; George S Deepe
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 9.  IL-13 receptor isoforms: breaking through the complexity.

Authors:  Yasuhiro Tabata; Gurjit K Khurana Hershey
Journal:  Curr Allergy Asthma Rep       Date:  2007-09       Impact factor: 4.806

Review 10.  Immunotoxin therapy for CNS tumor.

Authors:  Edward Rustamzadeh; Walter C Low; Daniel A Vallera; Walter A Hall
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.